Autres langues Aurinia Pharmaceuticals Inc.

Actions

AUPH

CA05156V1022

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
5,03 ^USD	-1,18 %		+2,44 %	-44,05 %

20/03	ILJIN SNT envoie une lettre à Aurinia Pharmaceuticals	CI
07/03	Un initié d'Aurinia Pharmaceuticals a vendu des actions pour une valeur de 711 094 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	17/04
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	16/04
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	15/04
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	20/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	07/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	07/03
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	29/02
Aurinia to Participate in Upcoming Investor Healthcare Conferences	27/02
Sector Update: Health Care Stocks Higher Late Afternoon	15/02
Sector Update: Health Care Stocks Higher Thursday Afternoon	15/02
Sector Update: Health Care	15/02
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	15/02
Aurinia: Q4 Earnings Snapshot	15/02
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	15/02
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aurinia Pharmaceuticals Inc.

Actions

AUPH

CA05156V1022

Autres langues

Filtres